Tharimmune, Inc. (NASDAQ:THAR) Sees Large Decline in Short Interest

Tharimmune, Inc. (NASDAQ:THAR) was the target of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 60,500 shares, a decrease of 32.3% from the December 15th total of 89,300 shares. Currently, 4.2% of the shares of the company are sold short. Based on an average daily volume of 1,230,000 shares, the short-interest ratio is presently 0.0 days.

Institutional Trading of Tharimmune

A hedge fund recently bought a new stake in Tharimmune stock. Curi RMB Capital LLC acquired a new position in Tharimmune, Inc. (NASDAQ:THAR) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned approximately 2.06% of Tharimmune as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 1.16% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on THAR. RODMAN&RENSHAW upgraded Tharimmune to a “strong-buy” rating in a research note on Friday, December 6th. Rodman & Renshaw started coverage on shares of Tharimmune in a research note on Friday, December 6th. They issued a “buy” rating and a $17.00 price objective for the company.

Tharimmune Trading Up 0.5 %

Shares of THAR opened at $2.00 on Friday. The business’s 50-day moving average price is $2.19 and its 200-day moving average price is $2.63. Tharimmune has a twelve month low of $1.84 and a twelve month high of $7.71.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).